A major finding from the present study was the impact of adjuvant systemic treatment, which is connected to tumor type, because specific drugs are restricted to patients with Her-2-positive disease, while triple-negative histology restricts adjuvant options in a broader sense, especially in the earlier years of this study before capecitabine was introduced. This evidence concerns the gene ERBB2 and neoplasm.